• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单发性和多发性大肝细胞癌根治性切除术后复发的部位和时间模式:一项多中心国际综合分析

Patterns of Site and Timing of Recurrence After Curative Resection in Single and Multiple Large Hepatocellular Carcinoma: A Multicenter International Comprehensive Analysis.

作者信息

Giannone Fabio, Cassese Gianluca, Cubisino Antonio, Felli Emanuele, Cipriani Federica, Branciforte Bruno, Rhaiem Rami, Tropea Alessandro, Muttillo Edoardo Maria, Scarinci Andrea, Al Taweel Bader, Brustia Raffaele, Salame Ephrem, Sommacale Daniele, Gruttadauria Salvatore, Piardi Tullio, Grazi Gian Luca, Torzilli Guido, Aldrighetti Luca, Lesurtel Mickael, Han Ho-Seong, Panaro Fabrizio, Pessaux Patrick

机构信息

Hepato-Pancreato-Biliary, Oncologic and Robotic Unit, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

Robotic and HPB Research Unit, Research and Innovation Department (DAIRI), Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

出版信息

Ann Surg Oncol. 2025 Jun 19. doi: 10.1245/s10434-025-17673-3.

DOI:10.1245/s10434-025-17673-3
PMID:40537677
Abstract

BACKGROUND

Curative options for large hepatocellular carcinoma (LHCC) are limited because of the high risk of early and extrahepatic recurrence. However, only a few studies report data on long-term outcomes in large cohorts of resected LHCC. We therefore investigated timing and site of recurrence of LHCC and assessed factors strictly associated with adverse patterns.

PATIENTS AND METHODS

This was a retrospective, international, multicenter study of patients undergoing anatomic resection of HCC ≥ 5 cm at 12 hepatobiliary high-volume centers. Extrahepatic recurrence was defined as any distant site of metastasis, while recurrence within 2 years after surgery was classified as early recurrence.

RESULTS

A total of 869 patients were included. Recurrence was observed in 487 (56%) cases. Patterns associated with reduced overall survival were early (p < 0.001) and simultaneous intrahepatic and extrahepatic recurrence (p = 0.038). Variables independently associated with early recurrence were age (p = 0.037), major hepatectomy (p = 0.023), microvascular invasion (p = 0.011), satellites nodules (p = 0.005), and open approach (p = 0.025). Variables correlated with simultaneous intra- and extrahepatic relapse were age (p < 0.001), preoperative transarterial chemoembolization (TACE) (p < 0.001), microvascular invasion (p < 0.001), and satellite nodules (p = 0.026).

CONCLUSIONS

Surgery for LHCC is associated with a high risk of early recurrence. Apart from pathological variables, factors independently associated with adverse patterns were open approach and age for the early recurrence and preoperative TACE and age for simultaneous intra-extrahepatic relapse. BCLC stage was not associated with timing nor with site of recurrence.

摘要

背景

由于早期和肝外复发风险高,大肝细胞癌(LHCC)的治疗选择有限。然而,仅有少数研究报告了大量切除的LHCC患者的长期预后数据。因此,我们研究了LHCC复发的时间和部位,并评估了与不良复发模式密切相关的因素。

患者与方法

这是一项回顾性、国际性、多中心研究,研究对象为在12个肝胆疾病高容量中心接受解剖性切除≥5 cm HCC的患者。肝外复发定义为任何远处转移部位,而术后2年内复发归类为早期复发。

结果

共纳入869例患者。487例(56%)出现复发。与总生存期降低相关的复发模式为早期复发(p<0.001)以及同时发生的肝内和肝外复发(p=0.038)。与早期复发独立相关的变量包括年龄(p=0.037)、大范围肝切除术(p=0.023)、微血管侵犯(p=0.011)、卫星结节(p=0.005)和开放手术入路(p=0.025)。与同时发生肝内和肝外复发相关的变量包括年龄(p<0.001)、术前经动脉化疗栓塞术(TACE)(p<0.001)、微血管侵犯(p<0.001)和卫星结节(p=0.026)。

结论

LHCC手术与早期复发的高风险相关。除病理变量外,与不良复发模式独立相关的因素,对于早期复发为开放手术入路和年龄,对于同时发生的肝内和肝外复发为术前TACE和年龄。BCLC分期与复发时间和部位均无关。

相似文献

1
Patterns of Site and Timing of Recurrence After Curative Resection in Single and Multiple Large Hepatocellular Carcinoma: A Multicenter International Comprehensive Analysis.单发性和多发性大肝细胞癌根治性切除术后复发的部位和时间模式:一项多中心国际综合分析
Ann Surg Oncol. 2025 Jun 19. doi: 10.1245/s10434-025-17673-3.
2
Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma.经皮乙醇注射或经皮乙酸注射治疗早期肝细胞癌。
Cochrane Database Syst Rev. 2015 Jan 26;1(1):CD006745. doi: 10.1002/14651858.CD006745.pub3.
3
Patterns and outcomes of early and late recurrence after hepatectomy for hepatocellular carcinoma with microvascular invasion: a multicenter study in China.伴有微血管侵犯的肝细胞癌肝切除术后早期和晚期复发的模式及结局:一项中国的多中心研究
Hepatol Int. 2025 Mar 10. doi: 10.1007/s12072-025-10802-w.
4
Prognostic Impact of the Pathologic Response of Patients with Hepatocellular Carcinoma After Preoperative Treatments.术前治疗后肝细胞癌患者病理反应的预后影响
Ann Surg Oncol. 2025 May 17. doi: 10.1245/s10434-025-17453-z.
5
A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma.一项关于 III A 期肝细胞癌辅助经动脉化疗栓塞术联合肝切除术与单纯肝切除术的随机对照试验。
J Cancer Res Clin Oncol. 2009 Oct;135(10):1437-45. doi: 10.1007/s00432-009-0588-2. Epub 2009 May 1.
6
Efficacy and safety of laparoscopic liver resection versus radiofrequency ablation in patients with early and small hepatocellular carcinoma: an updated meta-analysis and meta-regression of observational studies.腹腔镜肝切除术与射频消融术治疗早期小肝癌的疗效和安全性:一项观察性研究的更新荟萃分析和荟萃回归。
World J Surg Oncol. 2024 Feb 7;22(1):47. doi: 10.1186/s12957-023-03292-3.
7
Grading risk of microvascular invasion impacts survival in hepatocellular carcinoma patients undergoing adjuvant transarterial chemoembolization: A multicenter study.微血管侵犯分级对接受辅助性经动脉化疗栓塞的肝细胞癌患者的生存有影响:一项多中心研究。
Eur J Surg Oncol. 2025 Apr 24;51(8):110102. doi: 10.1016/j.ejso.2025.110102.
8
A prognostic score based on early recurrence-related factors for hepatocellular carcinoma patients with microvascular invasion after hepatectomy.基于早期复发相关因素的肝切除术后微血管侵犯肝细胞癌患者的预后评分
Langenbecks Arch Surg. 2025 Aug 1;410(1):237. doi: 10.1007/s00423-025-03823-4.
9
Recurrence and survival after robotic vs laparoscopic liver resection in very-early to early-stage (BCLC 0-A) hepatocellular carcinoma.极早期至早期(BCLC 0-A期)肝细胞癌机器人手术与腹腔镜肝切除术后的复发及生存情况
Surg Endosc. 2025 Mar;39(3):2116-2128. doi: 10.1007/s00464-025-11553-3. Epub 2025 Feb 4.
10
Impact of Anatomical Resection on Non-transplantable Recurrence Among Patients with Hepatocellular Carcinoma: An International Multicenter Inverse Probability of Treatment Weighting Analysis.解剖性切除对肝细胞癌患者不可移植性复发的影响:一项国际多中心治疗权重逆概率分析
Ann Surg Oncol. 2025 May 5. doi: 10.1245/s10434-025-17349-y.

引用本文的文献

1
ASO Author Reflections: Rethinking Recurrence Patterns After Resection of Large Hepatocellular Carcinoma: Time to Overcome the Current Staging Paradigm?ASO作者反思:大肝细胞癌切除术后复发模式的重新思考:是时候突破当前的分期模式了吗?
Ann Surg Oncol. 2025 Jul 2. doi: 10.1245/s10434-025-17774-z.

本文引用的文献

1
Prognostic benefit of preoperative transarterial chemoembolization in upfront resectable large hepatocellular carcinoma: a multicentric propensity score based analysis of European high-volume centers.术前经动脉化疗栓塞对可直接切除的大肝癌的预后获益:来自欧洲大容量中心的多中心倾向评分匹配分析。
HPB (Oxford). 2024 Jun;26(6):840-850. doi: 10.1016/j.hpb.2024.03.1159. Epub 2024 Mar 20.
2
Role of microvascular invasion in early recurrence of hepatocellular carcinoma after liver resection: A literature review.微血管侵犯在肝切除术后肝细胞癌早期复发中的作用:文献综述。
Asian J Surg. 2024 May;47(5):2138-2143. doi: 10.1016/j.asjsur.2024.02.115. Epub 2024 Mar 5.
3
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy.
全球肝细胞癌流行病学趋势:对筛查、预防和治疗的启示。
Nat Rev Clin Oncol. 2023 Dec;20(12):864-884. doi: 10.1038/s41571-023-00825-3. Epub 2023 Oct 26.
4
Preoperative transarterial chemoembolization (TACE) + liver resection versus upfront liver resection for large hepatocellular carcinoma (≥5 cm): a systematic review and meta-analysis.术前经动脉化疗栓塞术(TACE)联合肝切除术与直接肝切除术治疗大肝细胞癌(≥5厘米)的系统评价和荟萃分析
Acta Chir Belg. 2023 Dec;123(6):601-617. doi: 10.1080/00015458.2023.2256539. Epub 2023 Sep 8.
5
Laparoscopic versus open hepatectomy for large hepatocellular carcinoma: a single center propensity-score-matching comparative analysis of perioperative outcomes and long-term survival.腹腔镜与开腹肝切除术治疗大肝癌:单中心倾向评分匹配的围手术期结局和长期生存的比较分析
Surg Endosc. 2023 Apr;37(4):2997-3009. doi: 10.1007/s00464-022-09812-8. Epub 2022 Dec 15.
6
Early extrahepatic recurrence as a pivotal factor for survival after hepatocellular carcinoma resection: A 15-year observational study.早期肝外复发是肝癌切除术后生存的关键因素:一项 15 年观察性研究。
World J Gastroenterol. 2022 Sep 28;28(36):5351-5363. doi: 10.3748/wjg.v28.i36.5351.
7
Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial).手术与射频消融治疗小肝癌:一项随机对照试验(SURF试验)。
Liver Cancer. 2021 Dec 29;11(3):209-218. doi: 10.1159/000521665. eCollection 2022 Jun.
8
Liver resection for large and huge hepatocellular carcinoma: Predictors of failure, recurrence patterns, and prognoses.大肝癌和巨大肝癌的肝切除术:失败的预测因素、复发模式及预后
Asia Pac J Clin Oncol. 2023 Apr;19(2):e60-e70. doi: 10.1111/ajco.13777. Epub 2022 Apr 11.
9
Patterns, treatments, and prognosis of tumor recurrence after resection for hepatocellular carcinoma with microvascular invasion: a multicenter study from China.肝细胞癌微血管侵犯切除术后肿瘤复发的模式、治疗和预后:来自中国的多中心研究。
HPB (Oxford). 2022 Jul;24(7):1063-1073. doi: 10.1016/j.hpb.2021.11.016. Epub 2021 Dec 3.
10
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.BCLC 策略用于预后预测和治疗推荐:2022 年更新版。
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.